Introduction
The octapeptide, angiotensin II (Ang II), is the major effector molecule of the renin-angiotensin-system (RAS), and exerts a multitude of actions. Besides being the classically recognised potent vasoconstrictor, Ang II is capable of inducing cell proliferation, and is as such probably contributing, under pathologic conditions, to structural alterations in various organs. Thus, Ang II is considered an important factor in cardiovascular pathology, such as cardiac left ventricular hypertrophy and fibrosis, vascular media hypertrophy, or neointima formation, and structural alterations of the heart and kidney, like postinfarct remodelling and nephrosclerosis. In recent years it has become more evident that the RAS also plays a major role in the development and maintenance of arterial hypertension and numerous approaches have been undertaken to pharmacologically interfere with the system. In most cases, the primary therapeutic goal was to lower elevated blood pressure. However, since the development of angiotensinconverting enzyme (ACE) inhibitors, experimental and clinical studies have established that, besides the decrease in blood pressure, drugs like ACE inhibitors or angiotensin AT 1 -receptor antagonists can exert further beneficial actions independently of blood pressure. These include a reduction in vascular 1 and post-myocardial-infarction remodelling 2 or preservation of kidney function in (diabetic) nephropathy. 1, 3, 4 Correspondence: Prof. Dr. med. Thomas Unger, Institute of Pharmacology, University of Kiel, Hospitalstr. 4, D-24105 Kiel, Germany tors have been shown to exert counteracting effects on cellular growth and differentiation, vascular tone and the release of arginine vasopressin (AVP). In each condition the AT 2 receptor appears to down-modulate actions mediated by the AT 1 receptor, resulting in decreased cellular proliferation, decreased levels of serum AVP levels or decreased vasoconstrictor responses. In addition, in neuronal cell lines, the AT 2 receptor reportedly exerts antiproliferative effects and promotes neurite outgrowth, an effect accompanied by significant changes in the gene expression pattern of growth-and differentiation-related genes.
ACE is not the only enzyme leading to Ang II formation, since other enzymes such as chymase 5 (which is believed to substantially contribute to Ang II formation in the human heart), 6 CAGE, cathepsin G, 7, 8 tPA, elastase, 9 tonin, 10 and others can also generate Ang II. Furthermore, ACE is identical to kininase II, an enzyme degrading bradykinin and other kinins to inactive metabolites. A blockade of ACE is, therefore, associated with a potentiation of endogenous kinins, a mechanism thought to contribute to desirable effects of ACE inhibitors such as the organ protection. 11 Unfortunately, this was also associated with some unwarranted effects, for example, dry cough (limiting the use of ACE inhibitors in approximately 10% of patients).
Development of Ang II-receptor binding substances
In an endeavour to block the RAS more specifically at the level of its receptors, peptidergic Ang II-receptor antagonists were developed. As the first of its class, saralasin (Sar1 Ile8-Ang II) was introduced in 1971. 12 However, saralasin and further antagonists, such as sarilesin or sarmesin, were all based on a peptide structure that precludes oral administration. 13, 14 Besides their lack of bioavailability, they also featured the disadvantage of having a short duration of action and a high intrinsic activity by themselves. 13 Furthermore, since they were unable to discriminate between the different Ang II-receptor subtypes, they unselectively block all available Ang II receptors.
In 1982, imidazole-5-acetic acid derivatives were issued, 15 and it was soon recognised that these com-pounds could antagonise Ang II-induced vasoconstriction in isolated vessels. This was the basis for the further development of highly specific and selective angiotensin AT 1 -receptor binding substances such as losartan, [16] [17] [18] [19] valsartan, [20] [21] [22] [23] irbesartan, [24] [25] [26] [27] candesartan, 28 eprosartan, 29 telmisartan, 30 and others (overview 31 ), and AT 2 -receptor ligands/antagonists, for example, PD123177, PD123319, and CGP42112. 32, 33 Ang II receptor subtypes
In the past, both the short-and long-term effects of Ang II were thought to be mediated by a single receptor. The development of highly specific and selective AT 1 -receptor antagonists was the basis for the identification of the Ang II-receptor subtypes. Generally recognised are the AT 1 and AT 2 receptors, which display a heterogeneous distribution in peripheral tissues and the brain. [34] [35] [36] In rodents and Xenopus, the AT 1 -receptor subtype exists as two isoforms, namely the AT 1a and the AT 1b receptor. 37, 38 Sequence information from humans also suggests the existence of a second AT 1 receptor, [39] [40] [41] but so far only a single AT 1 gene has been detected on chromosome 3. While AT 1a and AT 1b subtypes are more or less equally expressed in spleen, liver and kidneys, 37 ,38 the AT 1a receptor seems to be predominant in vascular smooth muscle, heart, lung, ovary, and hypothalamus. 31, 37, 38 In vascular smooth muscle, mainly AT 1a receptors are found, suggesting that this subtype plays a role in vasoconstriction. Because the AT 1b -receptor subtype seems to prevail in the anterior pituitary, adrenal gland, uterus, and several periventricular brain areas, 31, 38, 42, 43 this receptor may be involved in hormonal secretion and central osmotic control.
Sequence information obtained after polymerase chain reaction cloning suggests the existence of a third AT 1 (AT 1c ) subtype in the rat, 44 but like the putative AT 1 -receptor subtype in humans, no chromosomal localisation has been identified for the rat AT 1c -receptor subtype. The AT 1 receptor belongs to the superfamily of 7-transmembrane domain, Gprotein coupled receptors. AT 1 -receptor cDNA has been obtained from a number of tissues, such as heart, liver, and placenta. The majority of the open reading frames encode for 359-amino acid receptors. The single human AT 1 -receptor gene has a minimum size of 60 kb and contains five exons, with the entire coding region within the fifth exon. [45] [46] [47] In rat and mouse, the AT 1a and AT 1b subtypes are highly homologous, and exhibit a 91% similarity on a nucleic acid, and a 96% similarity on an amino acid, level.
The human AT 1 -and rat AT 1a -receptor nucleic acid and amino acid sequences share an 86% and a 94% homology, respectively. The differences are not located in a particular region of the receptor, but are evenly spread throughout the coding region. The rat AT 1a gene has a size of at least 84 kb and is composed of four exons [48] [49] [50] with the entire coding sequence located in its last exon. The AT 1b gene is at least 15 kb long, consists of three exons, and encodes transcripts of approximately 2.4 kb in size. 51 Its coding region is located entirely in the third exon.
Different groups have reported that the AT 1 receptor interacts with various G-proteins and is coupled to one of the two heteromeric G-proteins: G q␣ or G i␣ . Ang II binding to specific sites on the extracellular and membrane-spanning portions of the AT 1 -receptor results in subsequent activation of phospholipases C, D, and A 2 via G q or inhibition of adenylate cyclase via G i , respectively. The phospholipase C activation results in the generation of 1, 4, 5-trisphosphate and diacylglycerol, leading to an activation of protein kinase C and an increase in intracellular calcium levels via L-type calcium channels. [52] [53] [54] The rise in intracellular calcium is associated with typical AT 1 -receptor-associated responses such as vasoconstriction and secretion of aldosterone. The cascade induced by phospholipase D and A 2 leads to the formation of fatty acids. Phospholipase D hydrolyses phosphatidylcholine into phosphatidic acid and choline. Phosphatidic acid and diacylglycerol can be inter-converted allowing the degradation of the latter to fatty acids and glycerol by diacylglycerol lipase. Phospholipase A 2 hydrolyses phosphatidylcholine and phosphatidylethanolamine into the corresponding lysophospholipids (C, E) and fatty acids. A fatty acid frequently released by phospholipase A 2 and diacylglycerol lipase is arachidonic acid, which is a precursor of leukotrienes and prostaglandins.
Phospholipase C exists in several isoforms that can be subdivided in three classes, namely PLC-b, PLC-g, and PLC-d. 55 The four b-isoforms are thought to be activated by subunits of G-proteins, whereas the g isoforms have to be activated by tyrosine phosphorylation. AT 1 receptor activation leads to the tyrosine phosphorylation of PLC-g1 in both rat smooth-muscle and glomerular mesangial cells. 56, 57 In smooth-muscle cells it has been shown that, for this purpose, the AT 1 receptor has to recruit the soluble tyrosine kinase pp60 c-src , since the receptor itself lacks intrinsic kinase activity. 58 PLC-g1 phosphorylation leads to the PIP 2 hydrolysis into 1,4,5-IP 3 and diacylglycerol. The induction of 1,4,5-IP 3 leads to intracellular calcium release, which in turn induces smooth-muscle cell contraction and other signaling events.
Ang II-induced cell hypertrophy and hyperplasia are both mediated through the AT 1 receptor. Protein kinase C, as well as elevated intracellular calcium ion (Ca 2+ ) levels, have been shown to promote the expression of the growth-related inducible transcription factors (ITFs) such as c-fos, c-myc and cjun. 59 The proteins encoded by the growth-related ITFs act as transcription factors for various target genes, which may be involved in the stimulation of mitogenesis. Ang II also induces, by stimulation of its AT 1 receptors, the transcription of plateletderived growth factor-␣ (PDGF-␣) chain and TGF-␤ 1 and, via this mechanism, is directly coupled to the expression of growth factors. 60, 61 Recent reports link Ang II, through the AT 1 receptor, to the Jak/STAT signalling pathway. 62 This is a significant observation since the Jak/STAT pathway has been previously identified for cytokine receptors Ang II receptor pharmacology O Chung et al S13 which leads to transcriptional activation of early growth-response genes, 63 and is now possibly also an important signalling pathway through which Ang II mediates its proliferative effects. 64 Interaction of Ang II with the Jak/STAT pathway has been observed in rat aortic smooth muscle cells. 65 Ang II is able to rapidly phosphorylate tyrosine of the kinases Jak2 and Tyk2. Stimulation of Jak activity also leads to the phosphorylation of both STAT1 and STAT2 proteins, and subsequent translocation to the nucleus of the STAT1 protein. In cultured neonatal fibroblasts, Bhat et al 66 showed that Ang II induces STAT protein phosphorylation and translocation of STAT proteins, leading to initiation of gene transcription. In neonatal rat cardiac myocytes cells, STAT1 and STAT3 are rapidly phosphorylated in response to Ang II, and coimmunoprecipitation experiments have shown that the AT 1 receptor is directly linked to components of the Jak/STAT pathway. 67 Also, antibodies against STAT proteins in vascular smooth muscle cells inhibit the Ang II mediated proliferative response. 68 A physical association between Jak2 kinase and a part of the intracellular carboxy tail of the AT 1 receptor has been shown. 69 Very recently it has been shown that Ang II mediates the Jak/STAT pathway under pathological conditions. 70 In contrast to the AT 1 receptor, much less is known about the structural and functional properties of the AT 2 receptor, which has been cloned recently from the mouse, rat, and human. 71, 72 In all three species, the AT 2 -receptor cDNA encodes for a 363-amino acid receptor, and sequence comparison reveals an expectedly high homology on both the nucleic and amino acid level (human and rat AT 2 receptor cDNA share a homology of 89% and 91% on nucleic acid and amino acid level, respectively). Both mouse and human AT 2 receptor genes are located on the x chromosome. 73, 74 The human AT 2 -receptor gene consists of three exons with its entire coding region located in the third exon. 75, 76 The AT 2 -receptor cDNA has been isolated from a number of tissues and from whole rat and mouse fetuses. Comparing the AT 1 -and AT 2 -nucleic acid sequences reveals a lack of homology (only a 34% identity). In the adult organism, the AT 2 receptor is present at high concentrations in the adrenal medulla, uterus, and ovary, and is also found in vascular endothelium and in distinct brain areas. 14, 20 The fact that it is expressed at high levels in embryonic tissues, but to a much lesser extent in normal adult tissues, has raised speculations as to its possible role in development and cell differentiation.
The molecular structure and signal transduction pathways of the AT 2 receptor are far from being completely understood, and it is still controversial whether or not the AT 2 receptor is coupled to Gproteins, and how it signals. Kambayashi et al 71 reported that the rat AT 2 receptor inhibits a phosphotyrosine phosphatase in COS-7 cells, kidney cells from African green monkeys, stably expressing the rat AT 2 receptor. This effect is dependent on a pertussis-toxin-sensitive, G-protein-coupled mechanism. Further evidence in support of AT 2 54 found that AT 2 receptor stimulation results in the inhibition of T-type calcium channels through an as yet undefined pathway. [52] [53] [54] In another cell line from rat pheochromocytoma, PC12W, which only expresses AT 2 receptors, Bottari and colleagues 60, 78 reported that Ang II stimulates a membrane-associated phosphotyrosine phosphatase and inhibits ANP-sensitive particulate guanylate cyclase via a G-protein-independent pathway.
The relationship between AT 2 -receptor by mediated signalling and tyrosine phosphorylation, 71, 78 as well as the fact that the AT 2 -receptor subtype is highly and transiently expressed in foetal tissues, followed by a dramatic drop in most organs just after birth, 79 suggests that this receptor plays a role in physiologic processes involving cellular growth, differentiation, and adhesion. Studies from our laboratory have demonstrated that angiotensin peptides can exert an antimitogenic action on rat and bovine endothelial cells of different origins via the AT 2 receptor, suggesting that Ang II exerts differential growth-modulating actions depending on the presence or absence of Ang II-receptor subtypes on a given cell. [80] [81] [82] In further studies in PC12W cells, we also demonstrated that Ang II inhibits serum-and epidermal growth factor-induced proliferation and potentiates the nerve growth factor-and epidermal growth factor-mediated growth inhibition through its AT 2 receptor. 83 Our results are supported by recent findings by Nakajima et al 84 who attempted to characterise the role of the AT 2 receptor in the model of neointima formation in the balloon-injured rat carotid artery. In this in vivo gene transfer study, the AT 2 receptor was transfected to the injured vessel, and the formation of neointima was studied in the presence or absence of the AT 2 receptor. Morphometric analysis performed 14 days after balloon injury revealed that myointima size was reduced by 70% in the presence of the AT 2 receptor. This effect could be reversed by the AT 2 antagonist, PD 123319, suggesting that the expressed AT 2 receptor mediated the inhibiting effect on neointima formation. It appears from these studies that, under physiologic conditions, one of the functions of the AT 2 receptor in the vasculature consists of the inhibition of angiogensis.
Under pathophysiologic conditions, the expression of the AT 2 receptor may be increased to control excessive growth mediated via the AT 1 receptor or via other growth factors. This may be relevant to neointima proliferation, 85 post-myocardial infarction adaptation, and left ventricular hypertrophy. 86, 87 Recent reports indicate a role for the AT 2 receptor in blood pressure regulation as well. Ang II causes an enhanced depressor response in rats when AT 1 receptors are blocked. This effect is blocked by PD 123177. 88 Also, coinfusion of rats with Ang II and PD 123199 results in an enhanced blood pressure response, as compared to rats infused with Ang II alone. 89 Although the AT 2 receptor seems to be involved in growth and differentiation, lack of a functional receptor still allows for development of an organism, as illustrated by the establishment of AT 2 knockout mice strains. Data obtained from these mice links the AT 2 receptor to behaviour and to altered blood pressure regulation.
90,91

Pharmacologic properties of AT 1 antagonists
The AT 1 receptor antagonists, the 'sartans' (Figure  1a-g ), are novel in regard to at least two aspects: first, they afford a highly specific and selective blockade of the angiotensin AT 1 receptor subtype and are void of any intrinsic activity; 87 second, they are, in contrast to saralasin and other earlier developed peptide antagonists, based on a nonpeptide structure that renders them suitable for oral administration. 87 AT 1 antagonists are generally well tolerated, and have a low profile of side effects, which in most studies is not significantly different from placebo. However, even though all of the sartans seem to bear overwhelming similarities, it is still necessary to scrutinise their chemical background and their pharmacologic properties, because subtle differences may have an important clinical impact. For example, as these molecules were derived from the same initially described imidazole derivatives, most of them feature two heterocyclic structures at a biphenyl structure.
However, some of the more recently developed AT 1 antagonists display significant differences from this concept in their chemical structure: valsartan, for example, is a tetrazole-biphenyl-valine derivative with only one heterocyclic structure at position 4Ј, and eprosartan lacks the biphenyl structure altogether. While some of the sartans, such as irbesartan, valsartan, eprosartan, and telmisartan can be administered in their active forms, while others, for example candesartan, are administered as an inactive prodrug, which then is converted in vivo into the active form. Losartan, which features a somewhat reduced AT 1 -receptor blocking property by itself, is converted in vivo to its more potent metabolite EXP3174, 92 which then appears to be responsible for most of the clinical effects.
The mode of action at the receptor site can also be different among the sartans. Some, as for example candesartan, valsartan, irbesartan, and EXP3174, achieve AT 1 -receptor blockade with an antagonism that has been designated 'insurmountable', 21, 92, 93 meaning that they cannot be readily displaced, even by very high concentrations of Ang II, while others, such as losartan and eprosartan, are strong competitive antagonists for Ang II at the AT 1 receptor, and, therefore, can be more readily displaced by high concentrations of Ang II at their binding sites.
Losartan
Losartan is a imidazole-derivative with a biphenyltetrazol side chain (Figure 1a) , which is considered to be essential for the Ang II-receptor binding properties. 19 Losartan, in a first-pass metabolisation in the liver, is in part oxidized at the imidazole ring to the active metabolite, EXP3174 (Figure 1b) , 92 which substantially contributes to most of the pharmacodynamic and pharmacokinetic properties observed.
Losartan has a 10-times lower affinity to the AT 1 receptor than does Ang II. Its selectivity for the AT 1 receptor is 3000-fold higher than the that for the AT 2 receptor, 19 with a binding affinity (IC 50 ) to the AT 1 receptor of 19 nmol/L. 19 Despite the fact that losartan binding to the AT 1 receptor is sufficient to result in an effective receptor blockade, it is lower when compared to some other AT 1 antagonists, whose IC 50 values range from 1.5 to 4 nmol/L. 21, 26, 93, 94 However, the binding affinity of EXP3174 ( IC 50 of 3.7 nmol/L), 19 is substantially higher, and is within the range of other AT 1 antagonists. The affinity of EXP3174 for the AT 1 receptor is 30 000-fold higher than that for the AT 2 receptor. 19 While losartan itself acts as a pure competitive antagonist, its active metabolite, EXP3174, also suppresses the effectmaximum of Ang II, and therefore displays noncompetitive properties. 95, 96 Thus, losartan features competitive as well as non-competitive antagonism. The oral bioavailability of losartan is approximately 33%. 18, 97 Peak plasma concentrations (T max ) of losartan after oral administration are observed after 1 h, and after 3 to 4 h for EXP3174. 18, 97 The terminal halflife of losartan is 2 h, that of EXP is 6 to 9 h. 18, 97 Ten hours after oral losartan administration, no significant plasma concentrations can be measured, while EXP3174 still reveals measurable concentrations after 24 h. Therefore, it is likely that EXP3174, more than losartan itself, contributes to the 24-h effectiveness of losartan. Both losartan and EXP3174 display high binding to plasma proteins (mainly albumin) of 98.7% and 99.8%, respectively. 98 The distribution volume for losartan was calculated to be 34 L, that of EXP3174 is 12 L. 97 Approximately 14% of an applied losartan dose is actually converted into EXP3174 in the liver. 18, 97 In addition, inactive oxidized and glucuronic acid coupled metabolites are equally produced.
The metabolism includes the pathway of the P 450 isoenzymes 2C9 and 3A4. Total clearance of losartan is 600 ml/min, that of EXP3174 is 50 ml/min. The renal clearance of losartan is 75 ml/min, that of EXP is 25 ml/min. Radioactively labelled losartan is excreted to 35-43% in urine and to 55-60% in faeces. 99 Unmetabolised losartan in urine accounts for approximately 5% of the administered dose. 99 In healthy volunteers and hypertensive patients, an uricosuric effect of losartan was observed. 100 This effect might be due to a benzbromarone-structure in the losartan molecule, which is also contained in substances used for uricosuric therapy. So far, this uricosuric property has only been described for losartan, but not for EXP3174 or other AT 1 antagonists.
Valsartan
Valsartan is a tetrazol-biphenyl-valine derivative and features only one heterocyclic structure in its Ang II receptor pharmacology O Chung et al S16 molecule (Figure 1c) . 20 It displays non-competitive antagonism at the AT 1 receptor. The K i for the AT 1 receptor in smooth-muscle cells is 2.4 nmol/L, the one for the AT 2 receptor in human myometrium membranes is 57.7 mol/L, therefore, the selectivity for the AT 1 over the AT 2 receptor is about 30 000-fold. 21 In human adrenal glands, the IC 50 was determined to be 2.6 nmol/L, a value comparable to the other mentioned AT 1 antagonists. 22 After oral administration, valsartan is absorbed quickly, with a T max at 2 h. Bioavailability is 25%, and is reduced by 46% with concomitant food intake. 101 Valsartan has a protein binding of 94% to 97%, mostly to albumin. 101 The distribution volume was calculated to be 17 L. Fully 30% of an intravenous dose is excreted unchanged in urine, and about 70% is excreted in the faeces. After oral administration, 13% of the administered dose appears unchanged in urine, the rest (83%) is excreted via the faeces. 101 So far, in contrast to all other AT 1 antagonists, no metabolites could be found for valsartan, which might be due to its unique chemical structure. Valsartan displays no clear dose linearity for plasma concentration, as the area under the plasma concentration-time curve (AUC) is less than proportional to the administered dose. 101 Total clearance is 36.7 ml/min. Renal clearance accounts only for about 30% of the total plasma clearance. In patients with hepatic insufficiency, the dosage of valsartan has to be reduced, as in these patients an increased C max and a two-fold increased AUC have been described.
Irbesartan
Like losartan, irbesartan is also an imidazole-derivative with a biphenyl-tetrazol-side chain ( Figure  1d) . 26 In human smooth-muscle cells, irbesartan has an about 10 times higher affinity for the AT 1 receptor, as compared to losartan. The IC 50 was measured in various isolated tissues, for example, aorta, ileum, and in cultured cells, and values ranged from 0.8 to 4.1 nmol/L. 26, 102 The IC 50 for the AT 2 receptor is reported to be 10 mol/L, the selectivity factor for the AT 1 receptor over the AT 2 receptor is, therefore, in the range of 10 000-fold. 102 In the rabbit aorta, irbesartan (1-10 nmol/L) leads to a dose-dependent blockade of Ang II-induced contractions. 102 As these effects cannot be reversed, even with high concentrations of Ang II, an insurmountable antagonism is present.
Resorption after oral administration is fast. Bioavailability is 60-80%, and thus higher as that of most other AT 1 antagonists. The terminal half-life after oral application is 11-15 h. 102 After intravenous administration, half-life was calculated as 13 h. T max was measured to be in the range of 1-3.5 h, depending on the dose administered per os. 102 Approximately 60% to 80% of an orally administered irbesartan dose is excreted via faeces, while about 25% of an orally administered and 23% of an intravenously administered dose appear in urine. However, as irbesartan is strongly metabolised via hepatic glucuronidation and oxidation, only about 1% is excreted as the unchanged molecule. In vitro studies suggest that irbesartan is mainly oxidized via the P450 isoenzyme 2C9, and that oxidation via the isoenzyme 3A4 plays only a minor role.
So far, eight metabolites of irbesartan could be identified, including 6% glucuronide metabolites and to 9% COOH-derivatives, which were found in the plasma. No active metabolite of irbesartan has been described. Binding to plasma proteins is 90-92%, comparatively low. A dose linearity for the AUC has been shown in therapeutic doses. 102 Total clearance is 157-176 ml/min, mean renal clearance after oral administration is only 3-3.5 ml/min. A distribution volume of 53 L has been reported.
Candesartan-cilexetil/candesartan
Candesartan-cilexetil is a prodrug suitable for oral use (Figure 1e ). It is rapidly converted to the active drug, candesartan (Figure 1f) , by ester hydrolysis during absorption from the gastrointestinal tract. Candesartan displays high selectivity for AT 1 receptors, with tight binding to and slow dissociation from the receptor. 103 In displacement studies using rabbit aortic membranes, the affinity of candesartan to the AT 1 receptor was approximately 80 and 10 times higher than that of losartan and EXP3174, respectively. 104 Candesartan displays an 'insurmountable' antagonism at the AT 1 receptor, in experiments using inhibition of Ang II-induced contraction of rabbit aorta. 105 After oral administration, candesartan-cilexetil is converted to candesartan, with an average absolute bioavailability of candesartan of approximately 40%. The AUC of candesartan is not significantly affected by food intake. 28, 106 T max is reached 3-5 h after oral administration. Serum concentrations (AUC) displayed dose linearity with increasing doses in the therapeutic dose range. 107 No sex-related differences in the pharmacokinetics have so far been observed.
Candesartan is highly bound to plasma protein (Ͼ99%). 28, 106 Candesartan is mainly eliminated unchanged via urine and bile, and is only to a minor extent inactivated by hepatic metabolism. So far, only one inactive metabolite (CV15959) has been described. The terminal half-life of candesartan is 5-9 h, and no significant accumulation after multiple doses was observed (plasma concentrations +3% to +17%). 107 Total plasma clearance of candesartan is about 0.37 ml/min/kg, with a renal clearance of about 0.19 ml/min/kg. After an oral dose of candesartan cilexetil, about 20-30% is excreted in urine, and 60-70%, in faeces. The apparent volume of distribution of candesartan is 0.1 L/kg.
Eprosartan
Eprosartan is an imidazole-5-acrylic acid derivative, and contains, in contrast to the other AT 1 antagonists, no biphenyle structure (Figure 1g ). It has a high affinity to the AT 1 receptor with an IC 50 of 1.5 nmol/L (rat mesenteric artery) and 9.2 nmol/L in membrane preparations from the adrenal gland. 29 Eprosartan is already present in its active form, and features competitive antagonism for Ang II at the AT 1 receptor. 29 Oral resorption is fast, and maximal plasma conAng II receptor pharmacology O Chung et al S17 centrations of eprosartan occur 1-2 h after administration. 30 However, compared to the other AT 1 antagonists (bioavailability, 25-80%), eprosartan features a low bioavailability of only 13%, limited by a low absorption after oral administration rather than by a high first-pass metabolism. After intravenous administration, 61% is excreted via the faeces, and 37%, via urine, indicating biliar and renal excretion. Twenty percent is excreted in the urine as an acylglucuronide metabolite, and 80% is excreted unchanged. Due to the low absorption after oral administration, 90% is excreted via the faeces, and only 7% via urine.
No active metabolite of eprosartan has so far been described. In young healthy volunteers, the terminal half-life after intravenous administration was about 2 h, and after oral administration, 4.5-9 h. Binding to plasma proteins is high, and described to be between 97.9-98.6% up to plasma concentrations of 10 000 ng/ml, independent of concentration. A dose linearity for plasma concentrations has been shown for lower doses, however, a nonlinear relationship is found in higher doses. The distribution volume is 13 L. Total clearance is 130 ml/min, mean renal clearance after oral administration is 30-40 ml/min.
Conclusion
The characterisation of the Ang II-receptor subtypes has offered new tools to advance our knowledge on the various functions of Ang II. With the development of the nonpeptidergic AT 1 antagonists, the sartans, a new therapeutic mechanism for the treatment of hypertension could be introduced into clinical practice. The sartans specifically block the AT 1 receptor and feature low toxicity combined with high therapeutic safety. Furthermore, AT 1 -receptor antagonists have been shown to improve cardiac and vascular structure and function similar to the action of ACE inhibitors. The mechanisms for these additional effects of AT 1 blockers are not yet fully understood. As all of the AT 1 antagonists were developed on the basis of the initially described imidazole derivatives and act via a highly selective blockade of the AT 1 receptor, one would expect that their clinical actions are also similar. Nevertheless, significant differences can be found in their pharmacologic properties, and, with some of the more recently developed antagonists, in their chemical structures. Little, however, is known, as to how these differences actually might affect the clinical practice, but with an increasing number of patients treated with AT 1 antagonists and ongoing studies, further insights will develop over time.
